免费看裸体 视频阳春-免费看裸体 网水视频-免费看裸体 网站-免费看裸体 网站视频-免费看裸体 网站涂抹-免费看裸体 阳春

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 成人国产精品秘 在线看明星合成 | 国产粗语刺激对白性视频 | 国产裸体永久免费视频网站 | 国产真实乱婬A片三区高清蜜臀 | 银杏视频成人A片免费观看 日本欧美成人片AAAA | 无码人妻丰满熟妇**网站牛牛 | 女同调教女同老板 | 黄色片网站 | 国产精品高潮呻呤欠久A片 国产25页 | 国产午夜精品一区二区 | 免费看的黄色A网站 | 午夜精品久久久久久无码 | 久久久无码人妻精品无码 | 97超级碰碰碰碰碰碰碰碰碰 | 人妻精品一区二区在线 | 亚洲AV成人片色一区二区野牛 | 精品国产乱码久久久久夜深人妻 | 日韩AV综合 | 3d动漫精品啪啪一区二区 | 日韩成人影院 | HEYZO少婦AV無碼精品 | 三级国产精品 | 亚州成人 | 热播无码视频-高清无码视频大全-免费无码视频在线观看-第1页-A62AV | 高潮喷水在线观看 | 日韩亚洲欧美另类在线 | 91亚洲精品乱码久久久久久蜜桃 | 黄色A片免费看 | 国产无遮挡又黄又爽免费网站 | 朝桐光在线观看 | 无码午夜精品一区二区三区视频 | 琪琪无码午夜精品久久久久 | 午夜理论片yy4408私人影院 | 亚洲不卡高清视频 | 我爱97aⅴ| 少妇AV无码 | 国产 精品 无码 怀古装 | 视频一区二区在线 | 性影院内射一区 | 小视频你懂的 | 5566精品久久久久久无码 |